Hospitalization time [Mean±SD (Range)]; day | 3.7±1.1 (2–6) |
Complications (Clavien–Dindo); n(%) | |
Grade I | 0 (0) |
Grade II | 1 (5) |
Grade III | 1 (5) |
Grade IV | 0 (0) |
Grade V | 0 (0) |
Adverse events related with 99m TC or ICG use (<30 days); n (%) | 0 (0) |
Histotype; n (%) | |
Serous | 4 (20) |
Endometrioid | 8 (40) |
Mucinous | 2 (10) |
Clear cells | 5 (25) |
Other | 1 (5) |
Grade; n (%) | |
G1 | 8 (40) |
G2 | 0 (0) |
G3 | 11 (55) |
Not applicable (disgerminoma) | 1 (5) |
ILV; n (%) | 0 (0) |
FIGO stage; n (%) | |
IA | 7 (35) |
IC | 11 (55) |
IIA | 1 (5) |
IIIB | 1 (5) |
Pelvic LND [Mean±SD (Range)]; nodes | 20.1±7.6 (9–74) |
Para-aortic LND [Mean±SD (Range)]; nodes | 19.8±10.4 (6–40) |
Pelvic SLN removed [Mean±SD (Range)]; nodes | 2.2±1.5 (0–5) |
Para-aortic SLN removed [Mean±SD (Range)]; nodes | 3.3±1.8 (1–7) |
FIGO, The International Federation of Gynecology and Obstetrics; ICG, Indocyanine green; LND, lymphadenectomy; LVI, lymph vascular invasion; SLN, sentinel lymph node.